Gilead Sciences (GILD.US) announced that it had struck a licensing agreement to produce the antiviral drug remdesivir in 127 countries, not including the US. The company’s will work with five generic drugmakers to produce the potential drug for coronavirus. Among them is Mylan (MYL.US), which is the world's largest producer of generic drugs.

Gilead Sciences (GILD.US) shares rose 1.96% in pre-market trading. If positive mood persists, then resistance at $86.16 per share may be tested. Source: xStation5
Intel: Solid Results, But the Market Says "Not Enough"
Meta Platforms shares surge amid Jefferies 'Buy' recommendation 📈
US Open: Rebound attempt on Wall Street 📈Meta Platforms surges 3.5%
Stock of the Week: TSMC, the heart of the global AI revolution (January 22, 2026)